U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C13H10N2O4
Molecular Weight 258.2295
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of THALIDOMIDE

SMILES

O=C1N(C2CCC(=O)NC2=O)C(=O)C3=CC=CC=C13

InChI

InChIKey=UEJJHQNACJXSKW-UHFFFAOYSA-N
InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)

HIDE SMILES / InChI

Molecular Formula C13H10N2O4
Molecular Weight 258.2295
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020785s051lbl.pdf

Thalidomide is an immunomodulatory agent with a spectrum of activity that is not fully characterized. Thalidomide is racemic — it contains both left and right-handed isomers in equal amounts: one enantiomer is effective against morning sickness, and the other is teratogenic. The enantiomers are converted to each other in vivo. That is, if a human is given D-thalidomide or L-thalidomide, both isomers can be found in the serum. Hence, administering only one enantiomer will not prevent the teratogenic effect in humans. In patients with erythema nodosum leprosum (ENL) the mechanism of action is not fully understood. Available data from in vitro studies and preliminary clinical trials suggest that the immunologic effects of this compound can vary substantially under different conditions, but may be related to suppression of excessive tumor necrosis factor-alpha (TNF-a) production and down-modulation of selected cell surface adhesion molecules involved in leukocyte migration. For example, administration of thalidomide has been reported to decrease circulating levels of TNF-a in patients with ENL, however, it has also been shown to increase plasma TNF-a levels in HIV-seropositive patients. As a cancer treatment, the drug may act as a VEGF inhibitor. Thalidomide is used for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. Thalidomide is sold under the brand name Immunoprin, among others.

CNS Activity

Curator's Comment: Thalidomide, an inhibitor of TNF-α protein synthesis is readily capable of crossing the blood-brain barrier

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q96SW2
Gene ID: 51185.0
Gene Symbol: CRBN
Target Organism: Homo sapiens (Human)
Target ID: CHEMBL1825
200.0 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
THALOMID

Approved Use

THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM). THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.

Launch Date

9.0046077E11
Primary
THALOMID

Approved Use

THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM). THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.

Launch Date

9.0046077E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2 mg/L
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THALIDOMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
19.8 mg × h/L
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THALIDOMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.17 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THALIDOMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
45%
THALIDOMIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
400 mg/m2 1 times / day multiple, oral
MTD
Dose: 400 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg/m2, 1 times / day
Co-administed with::
Carboplatin, i.v(1/21 days)
Sources: Page: p.4397
unhealthy, 11
n = 10
Health Status: unhealthy
Condition: Cancer
Age Group: 11
Sex: M+F
Population Size: 10
Sources: Page: p.4397
DLT: Somnolence...
Dose limiting toxicities:
Somnolence (20%)
Sources: Page: p.4397
400 mg/m2 1 times / day multiple, oral
MTD
Dose: 400 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg/m2, 1 times / day
Co-administed with::
Carboplatin, i.v(1/21 days)
Sources: Page: p.4397
unhealthy, 11
n = 6
Health Status: unhealthy
Condition: Cancer
Age Group: 11
Sex: M+F
Population Size: 6
Sources: Page: p.4397
DLT: Ataxia...
Dose limiting toxicities:
Ataxia (16.7%)
Sources: Page: p.4397
150 mg 2 times / day multiple, oral
MTD
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources: Page: p.658
unhealthy, 57
n = 7
Health Status: unhealthy
Condition: Hepatocellular carcinoma
Age Group: 57
Sex: M+F
Population Size: 7
Sources: Page: p.658
200 mg 2 times / day multiple, oral
Studied dose
Dose: 200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 200 mg, 2 times / day
Sources: Page: p.658
unhealthy, 57
n = 2
Health Status: unhealthy
Condition: Hepatocellular carcinoma
Age Group: 57
Sex: M+F
Population Size: 2
Sources: Page: p.658
DLT: Dyspnea...
Dose limiting toxicities:
Dyspnea (50%)
Sources: Page: p.658
400 mg 1 times / day multiple, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Erythema nodosum leprosum
Sources: Page: p.1
Disc. AE: Fetal damage, Deep vein thrombosis...
AEs leading to
discontinuation/dose reduction:
Fetal damage
Deep vein thrombosis
Pulmonary embolism
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Somnolence 20%
DLT
400 mg/m2 1 times / day multiple, oral
MTD
Dose: 400 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg/m2, 1 times / day
Co-administed with::
Carboplatin, i.v(1/21 days)
Sources: Page: p.4397
unhealthy, 11
n = 10
Health Status: unhealthy
Condition: Cancer
Age Group: 11
Sex: M+F
Population Size: 10
Sources: Page: p.4397
Ataxia 16.7%
DLT
400 mg/m2 1 times / day multiple, oral
MTD
Dose: 400 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg/m2, 1 times / day
Co-administed with::
Carboplatin, i.v(1/21 days)
Sources: Page: p.4397
unhealthy, 11
n = 6
Health Status: unhealthy
Condition: Cancer
Age Group: 11
Sex: M+F
Population Size: 6
Sources: Page: p.4397
Dyspnea 50%
DLT
200 mg 2 times / day multiple, oral
Studied dose
Dose: 200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 200 mg, 2 times / day
Sources: Page: p.658
unhealthy, 57
n = 2
Health Status: unhealthy
Condition: Hepatocellular carcinoma
Age Group: 57
Sex: M+F
Population Size: 2
Sources: Page: p.658
Deep vein thrombosis Disc. AE
400 mg 1 times / day multiple, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Erythema nodosum leprosum
Sources: Page: p.1
Fetal damage Disc. AE
400 mg 1 times / day multiple, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Erythema nodosum leprosum
Sources: Page: p.1
Pulmonary embolism Disc. AE
400 mg 1 times / day multiple, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Erythema nodosum leprosum
Sources: Page: p.1
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Update on therapy--thalidomide in the treatment of lupus.
2001
Update on the treatment of multiple myeloma.
2001
Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing.
2001
A cybernetic theory of morality and moral autonomy.
2001 Apr
In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac.
2001 Apr
Thalidomide use: past history and current implications for practice.
2001 Apr
Treatment of severe esophageal Crohn's disease with thalidomide.
2001 Apr
High-dose therapy and innovative approaches to treatment of multiple myeloma.
2001 Apr
Multiple Myeloma. Advances in disease biology: therapeutic implications.
2001 Apr
Treatment of Behçet's disease--an update.
2001 Apr
Thalidomide-associated hepatitis: a case report.
2001 Apr
Development of a myeloproliferative disorder in a patient with monoclonal gammopathy of undetermined significance secreting immunoglobulin of the M class and treated with thalidomide and anti-CD20 monoclonal antibody.
2001 Apr 15
Pharmacotherapeutic options in inflammatory bowel disease: an update.
2001 Feb
Scleroderma.
2001 Feb
[Deep vein thrombosis and pulmonary embolism in a patient with aphtosis treated with thalidomide].
2001 Feb
[Thalidomide in treatment of Crohn disease: a new approach for managing chronic inflammation?].
2001 Feb
Thalidomide usage in Wales: the need to follow guidelines.
2001 Feb
Thalidomide.
2001 Feb
Demonstration of inhibitory effect of oral shark cartilage on basic fibroblast growth factor-induced angiogenesis in the rabbit cornea.
2001 Feb
Angiogenesis: regulators and clinical applications.
2001 Feb 1
[Discoid lupus, recurrent aphthosis. New indications for thalidomide?].
2001 Feb 22
Severe cutaneous ulceration following treatment with thalidomide for GVHD.
2001 Jan
[Suppression of synthesis of tumor necrosis factor].
2001 Jan
[Thalidomide: the revival].
2001 Jan
Effect of angiogenic and antiangiogenic compounds on the outgrowth of capillary structures from fetal mouse bone explants.
2001 Jan
Treatment strategies for recurrent oral aphthous ulcers.
2001 Jan 1
Clinical aspects and management of AIDS-related Kaposi's sarcoma.
2001 Jul
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.
2001 Jul 15
Thalidomide-induced amenorrhoea: two cases.
2001 Jun
Alpha-glucosidase inhibitors with a 4,5,6,7-tetrachlorophthalimide skeleton pendanted with a cycloalkyl or dicarba-closo-dodecaborane group.
2001 Jun
Effectors of inflammation in actinic prurigo.
2001 Jun
Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity.
2001 Jun 22
[Thalidomide and thrombosis: three observations].
2001 Jun 9
[Management of severe skin disorders in sarcoidosis].
2001 Mar
Thalidomide-induced sensory neuropathy.
2001 Mar
Prognostic factors and current practice in treatment of myelofibrosis with myeloid metaplasia: an update anno 2000.
2001 Mar
Cutaneous lupus erythematosus.
2001 Mar
Specialist life - William McBride.
2001 Mar
Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report.
2001 Mar
Embryonic mouse submandibular salivary gland morphogenesis and the TNF/TNF-R1 signal transduction pathway.
2001 Mar 1
Thalidomide: near complete regression of extramedullary bulk in refractory multiple myeloma.
2001 Mar 10
Systemic lupus erythematosus.
2001 Mar 31
Successful thalidomide treatment of severe infantile Behçet disease.
2001 Mar-Apr
[Sarcoidosis: thalidomide treatment in ten patients].
2001 May
Enantioseparation of aminoglutethimide and thalidomide by high performance liquid chromatography or supercritical fluid chromatography on mono-2 and mono-6-O-pentenyl-beta-cyclodextrin-based chiral stationary phases.
2001 May
Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's disease.
2001 May
Synthesis and immunological activity of water-soluble thalidomide prodrugs.
2001 May
Thalidomide and its dermatologic uses.
2001 May
Intractable insomnia after cessation of treatment with thalidomide.
2001 May
Thalidomide inhibits granulocyte responses in healthy humans after ex vivo stimulation with bacterial antigens.
2001 May
Patents

Sample Use Guides

MM: 200 mg orally once daily. The recommended dose of dexamethasone is 40 mg/day on days 1-4, 9-12, and 17-20 every 28 days. • ENL: 100 to 300 mg/day for an episode of cutaneous ENL. Up to 400 mg/day for severe cutaneous ENL.
Route of Administration: Oral
The minimum dose of thalidomide used (1 uM) inhibited TNF-α production in HTLV-1-infected subjects in vitro.
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:39:23 UTC 2023
Edited
by admin
on Wed Jul 05 23:39:23 UTC 2023
Record UNII
4Z8R6ORS6L
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
THALIDOMIDE
EMA EPAR   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
K-17
Code English
KEVADON
Brand Name English
THALIDOMIDE [JAN]
Common Name English
THALIDOMIDE [HSDB]
Common Name English
Thalidomide [WHO-DD]
Common Name English
THALIDOMIDE [MART.]
Common Name English
2,6-DIOXO-3-PHTHALIMIDOPIPERIDINE
Systematic Name English
CONTERGAN
Brand Name English
THALIDOMIDE [VANDF]
Common Name English
DISTAVAL
Brand Name English
(±)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
Systematic Name English
PHARMION
Brand Name English
THALIDOMIDE [USAN]
Common Name English
N-PHTHALYLGLUTAMIC ACID IMIDE
Common Name English
.ALPHA.-PHTHALIMIDOGLUTARIMIDE
Common Name English
NSC-527179
Code English
MYRIN
Brand Name English
NSC-66847
Code English
N-(2,6-Dioxo-3-piperidyl)phthalimide
Systematic Name English
thalidomide [INN]
Common Name English
THALIDOMIDE [USP MONOGRAPH]
Common Name English
THALIDOMIDE [USP-RS]
Common Name English
NEUROSEDYN
Brand Name English
THALIDOMIDE [ORANGE BOOK]
Common Name English
1H-ISOINDOLE-1,3(2H)-DIONE, 2-(2,6-DIOXO-3-PIPERIDINYL)-, (±)-
Systematic Name English
CELGENE
Brand Name English
THALOMID
Brand Name English
2-(2,6-DIOXO-3-PIPERIDINYL)-1H-ISOINDOLE-1,3(2H)-DIONE
Systematic Name English
SOFTENON
Brand Name English
.ALPHA.-(N-PHTHALIMIDO)GLUTARIMIDE
Common Name English
PANTOSEDIV
Brand Name English
THALIDOMIDE [EMA EPAR]
Common Name English
3-PHTHALIMIDOGLUTARIMIDE
Systematic Name English
THALED
Brand Name English
THALIDOMIDE [MI]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 43890
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
FDA ORPHAN DRUG 80194
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
FDA ORPHAN DRUG 30788
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
WHO-ATC L04AX02
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
FDA ORPHAN DRUG 115598
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
FDA ORPHAN DRUG 43790
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
NDF-RT N0000008663
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
WHO-VATC QL04AX02
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
FDA ORPHAN DRUG 90795
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
EU-Orphan Drug EU/3/01/067
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
NDF-RT N0000008663
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
FDA ORPHAN DRUG 585417
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
FDA ORPHAN DRUG 110197
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
FDA ORPHAN DRUG 72092
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
NCI_THESAURUS C129820
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
FDA ORPHAN DRUG 114998
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
NCI_THESAURUS C1742
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
FDA ORPHAN DRUG 121898
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
FDA ORPHAN DRUG 187204
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
FDA ORPHAN DRUG 94995
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
NCI_THESAURUS C574
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
FDA ORPHAN DRUG 32188
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
EMA ASSESSMENT REPORTS THALIDOMIDE CELGENE (AUTHORIZED: MUTIPLE MYELOMA)
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
NCI_THESAURUS C54677
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
FDA ORPHAN DRUG 82594
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
LIVERTOX NBK548371
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
Code System Code Type Description
CAS
50-35-1
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
PRIMARY
NSC
527179
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
PRIMARY
RXCUI
10432
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
PRIMARY RxNorm
DAILYMED
4Z8R6ORS6L
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
PRIMARY
EPA CompTox
DTXSID9022524
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
PRIMARY
SMS_ID
100000089194
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
PRIMARY
RS_ITEM_NUM
1652500
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
PRIMARY
FDA UNII
4Z8R6ORS6L
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
PRIMARY
CHEBI
74947
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
PRIMARY
MESH
D013792
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
PRIMARY
PUBCHEM
5426
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
PRIMARY
NSC
66847
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
PRIMARY
DRUG BANK
DB01041
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
PRIMARY
IUPHAR
7327
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
PRIMARY
ChEMBL
CHEMBL468
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
PRIMARY
WIKIPEDIA
THALIDOMIDE
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
PRIMARY
EVMPD
SUB10958MIG
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
PRIMARY
CHEBI
9513
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
PRIMARY
NCI_THESAURUS
C870
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
PRIMARY
ECHA (EC/EINECS)
200-031-1
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
PRIMARY
INN
762
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
PRIMARY
DRUG CENTRAL
2616
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
PRIMARY
MERCK INDEX
M10673
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
PRIMARY Merck Index
HSDB
3586
Created by admin on Wed Jul 05 23:39:23 UTC 2023 , Edited by admin on Wed Jul 05 23:39:23 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Kd
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
TARGET -> INHIBITOR
BINDING
TARGET -> INHIBITOR
Dose-dependent interaction with the CRBN-DDB1 complex
IC50
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
CYP2C9 and CYP1A2 were also mediators in this reaction.
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY